An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revolution Medicines, Inc. (Nasdaq: RVMD) will report its financial results for the first quarter of 2024 on May 8, 2024, after market close. The company is focused on developing targeted therapies for patients with RAS-addicted cancers. A webcast hosted by senior management will discuss the financial results and corporate progress.
Revolution Medicines, Inc. (Nasdaq: RVMD) comunicherà i suoi risultati finanziari per il primo trimestre del 2024 l'8 maggio 2024, dopo la chiusura del mercato. L'azienda è focalizzata sullo sviluppo di terapie mirate per pazienti con tumori dipendenti da RAS. Un webcast condotto dalla direzione aziendale discuterà dei risultati finanziari e dei progressi aziendali.
Revolution Medicines, Inc. (Nasdaq: RVMD) informará sobre sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024, después del cierre del mercado. La compañía está enfocada en desarrollar terapias dirigidas para pacientes con cánceres adictos a RAS. Una transmisión web dirigida por la alta gerencia discutirá los resultados financieros y el progreso corporativo.
Revolution Medicines, Inc. (나스닥: RVMD)는 2024년 5월 8일에 2024년 첫 분기의 재무 결과를 시장 마감 후 보고할 예정입니다. 이 회사는 RAS 중독 암 환자를 위한 표적 치료법 개발에 중점을 두고 있습니다. 고위 경영진이 주재하는 웹캐스트에서 재무 결과 및 기업 진행 상황에 대해 논의할 것입니다.
Revolution Medicines, Inc. (Nasdaq : RVMD) publiera ses résultats financiers pour le premier trimestre de 2024 le 8 mai 2024, après la clôture du marché. La société se concentre sur le développement de thérapies ciblées pour les patients atteints de cancers dépendants du RAS. Un webinaire animé par la direction senior discutera des résultats financiers et de la progression de l'entreprise.
Revolution Medicines, Inc. (Nasdaq: RVMD) wird seine Finanzergebnisse für das erste Quartal 2024 am 8. Mai 2024 nach Börsenschluss bekannt geben. Das Unternehmen konzentriert sich auf die Entwicklung von zielgerichteten Therapien für Patienten mit RAS-abhängigen Krebsarten. Ein von der obersten Führungsebene geleitetes Webcast wird die Finanzergebnisse und den Unternehmensfortschritt erörtern.
Positive
None.
Negative
None.
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter 2024 on Wednesday, May 8, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc. Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS companion inhibitors for use in combination treatment strategies. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional RAS(ON) mutant-selective inhibitors in the company’s development pipeline include RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C).
FAQ
When will Revolution Medicines report financial results for the first quarter of 2024?
Revolution Medicines will report financial results for the first quarter of 2024 on May 8, 2024, after market close.
What is Revolution Medicines focused on?
Revolution Medicines is focused on developing targeted therapies for patients with RAS-addicted cancers.
Where can I access the webcast hosted by Revolution Medicines' senior management team?
You can access the live webcast and the archived webcast by visiting: https://ir.revmed.com/events-and-presentations.
revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.
